KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) EBT (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of EBT data on record, last reported at -$227.9 million in Q4 2025.

  • For Q4 2025, EBT fell 111.65% year-over-year to -$227.9 million; the TTM value through Dec 2025 reached -$379.6 million, up 17.61%, while the annual FY2025 figure was -$379.6 million, 17.61% up from the prior year.
  • EBT reached -$227.9 million in Q4 2025 per IONS's latest filing, down from -$128.4 million in the prior quarter.
  • Across five years, EBT topped out at $331.9 million in Q4 2023 and bottomed at -$227.9 million in Q4 2025.
  • Average EBT over 5 years is -$54.8 million, with a median of -$86.8 million recorded in 2021.
  • The widest YoY moves for EBT: up 848.79% in 2023, down 201.46% in 2023.
  • A 5-year view of EBT shows it stood at $254.9 million in 2021, then tumbled by 117.39% to -$44.3 million in 2022, then soared by 848.79% to $331.9 million in 2023, then crashed by 132.44% to -$107.7 million in 2024, then plummeted by 111.65% to -$227.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$227.9 million in Q4 2025, -$128.4 million in Q3 2025, and $123.5 million in Q2 2025.